Stealth Bio's SBT-272 Shows Encouraging Action In Huntington's Disease Animal Model

Stealth BioTherapeutics Corp MITO announced the presentation of new SBT-272 preclinical data and dosing of the first subject in its Phase 1 trial of SBT-272.

• The new data demonstrated behavioral and metabolic improvements with SBT-272 in a mouse model of Huntington's disease. 
• In the study, mice were treated for up to 8 weeks with daily SBT-272 and displayed significantly improved motor function than vehicle-treated mice. 
• SBT-272-treated mice also showed improved metabolism in multiple brain regions of the diseased animals.
• Also Read: Stealth BioTherapeutics Showcases New Nonclinical Data From Duchenne Muscular Dystrophy Program.
• The Phase 1 trial will enroll up to 64 healthy subjects across multiple cohorts. The study will evaluate the safety and tolerability of single and multiple ascending doses of SBT-272.
• The Company plans to initiate chronic toxicology studies in 2022. 
• Price Action: MITO shares closed 1.21% higher at $0.70 on Wednesday.